InvestorsHub Logo
Followers 22
Posts 1379
Boards Moderated 0
Alias Born 03/31/2017

Re: LilyGDog post# 349823

Tuesday, 03/02/2021 9:04:57 AM

Tuesday, March 02, 2021 9:04:57 AM

Post# of 403568
Brilacidin’s ability to disrupt viral integrity suggests Brilacidin likely is not subject to resistance developing due to coronavirus variants—unlike current COVID-19 treatments, such as monoclonal antibodies and convalescent plasma, and first-generation COVID-19 vaccines. This mechanism of action supports Brilacidin as a clearly differentiated antiviral in clinical development.

Innovation Pharmaceuticals’ Brilacidin for the Treatment of COVID-19 Receives FDA Fast Track Designation

Brilacidin in Phase 2 Clinical Trial of Innovation Pharmaceuticals - Brilacidin for Treating COVID-19.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News